Clinical Trials Directory

Trials / Sponsors / Nanjing IASO Biotechnology Co., Ltd.

Nanjing IASO Biotechnology Co., Ltd.

Industry · 11 registered clinical trials — 9 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingEque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Phase 1 / Phase 22026-05-10
RecruitingUB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Systemic Lupus Erythematosus, Lupus Nephritis
Phase 12025-10-27
Not Yet RecruitingStudy of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
AL Amyloidosis
Phase 22025-07-01
RecruitingUB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Large B-cell Lymphoma
Phase 12025-04-11
RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Multiple Myeloma
—2024-12-15
RecruitingA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Phase 32024-03-27
UnknownA Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of
Multiple Myeloma
Phase 12023-05-08
RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
Phase 12023-03-30
Not Yet RecruitingA Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANB
Multiple Myeloma
Phase 12022-04-01
Not Yet RecruitingA Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
B-cell Non-Hodgkin's Lymphoma
Phase 1 / Phase 22021-10-20
UnknownA Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple M
Multiple Myeloma
Phase 1 / Phase 22020-04-01